Jin Lu
Wilmington University
4 Papers
1 Citations
Jin Lu is an academic researcher from Wilmington University. The author has contributed to research in topics: Cancer & Triple-negative breast cancer. The author has an hindex of 1, co-authored 2 publications.
Chat about Author
Papers
Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase δ Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy.
Niu Shin,Matthew C. Stubbs,Holly Koblish,Eddy W. Yue,Maxim Soloviev,Brent Douty,Kathy Wang,Qian Wang,Mingming Gao,Patricia Feldman,Gengjie Yang,Leslie Hall,Michael Hansbury,Sybil O'Connor,Lynn Leffet,Robert Collins,Kamna Katiyar,Xin He,Paul Waeltz,Paul Collier,Jin Lu,Yun-Long Li,Yanlong Li,Phillip C.C. Liu,Timothy Burn,Maryanne B. Covington,Sharon Diamond,Dana Shuey,Alan Roberts,Swamy Yeleswaram,Greg Hollis,Brian W. Metcalf,Wenqing Yao,Reid Huber,Andrew P. Combs,Robert C. Newton,Peggy Scherle +36 more
TL;DR: The preclinical properties described here provide the mechanism of action and support clinical investigations of parsaclisib as a therapy for B-cell malignancies and may be useful in guiding further translational studies for the selection of patients with DLBCL who might benefit from PI3Kδ inhibitor treatment in future trials.
Immunogenic Cell Death-Relevant Damage-Associated Molecular Patterns and Sensing Receptors in Triple-Negative Breast Cancer Molecular Subtypes and Implications for Immunotherapy
TL;DR: A novel ICD-associated DAMPs subtyping system in TNBC is established and DAMPs expression might be a valuable biomarker for immunotherapy strategies, suggesting that the constructed DAMPs clustering had potential for Immunotherapy efficacy prediction.
Accelerated Apoptosis and Down-Regulated FMRP in Human Neuroblastoma Cells with CRISPR/Cas9 Genome Editing
Rong Zhang,Huifen Xu,Jin Lu,Ying Chen,Yahui Zhang,Li Xiao +5 more
TL;DR: Wang et al. as mentioned in this paper used RNA-guided CRISPR/Cas9 system to target the FMR1 5'-UTR sites in cultured human neuroblastoma cells.
2
Abstract 531: Activity of the selective FGFR 1, 2 and 3 inhibitor INCB054828 in genetically-defined models of triple-negative breast cancer
Phillip C.C. Liu,Brian D. Lehmann,Bruce Ruggeri,Darlise DiMatteo,Johanna M. Schafer,Jin Lu,Sang Hyun Lee,Luping Lin,Timothy Burn,Melody Diamond,Alla Volgina,Liangxing Wu,Gregory Hollis,Reid Huber,Jennifer A. Pietenpol,Peggy Scherle +15 more
TL;DR: Activity of the selective FGFR 1, 2 and 3 inhibitor INCB054828 in genetically-defined models of triple-negative breast cancer was associated with suppression of growth promoting pathways including Ras-MAPK and inhibition of cell viability.
1